CancerFax
Bleeding & Platelet Disorder

Understanding Hermansky-Pudlak Syndrome

Hermansky-Pudlak Syndrome is a rare inherited disorder causing oculocutaneous albinism, a bleeding tendency from platelet storage pool deficiency, and in some subtypes, progressive lung and bowel disease.

  • Autosomal recessive inheritance
  • Albinism with bleeding tendency
  • Multisystem monitoring needed
Most Common In
Both sexes (autosomal recessive)
Causative Genes
HPS1–HPS11
Key Feature
Albinism + platelet storage pool deficiency
Advanced Therapies
Antifibrotic agents, lung transplant evaluation

Condition Overview

Hermansky-Pudlak Syndrome (HPS) is a rare autosomal recessive disorder caused by mutations in one of several genes (HPS1 through HPS11) involved in forming specialized cellular structures called lysosome-related organelles. This leads to oculocutaneous albinism (reduced pigmentation of skin, hair, and eyes), a bleeding tendency due to platelet storage pool deficiency, and in some subtypes, progressive pulmonary fibrosis or granulomatous colitis.

Types and Subtypes

HPS is classified by the specific causative gene, which influences the pattern and severity of associated complications.

Symptoms and Signs

Symptoms span pigmentation, bleeding, vision, and in some subtypes, lung and bowel involvement.

Causes and Risk Factors

HPS is caused by inherited mutations affecting genes responsible for building specialized intracellular compartments.

Diagnosis and Investigations

Diagnosis combines clinical features of albinism and bleeding with specialized platelet and genetic testing.

Risk Stratification

Risk in HPS is best framed by subtype and degree of organ involvement rather than a traditional staging system.

Standard Treatment

Management is multidisciplinary, addressing bleeding risk, vision, and monitoring for pulmonary or bowel complications.

Advanced & Emerging Therapies

Management of pulmonary fibrosis in HPS increasingly draws on therapies developed for other fibrotic lung diseases.

  • Antifibrotic Therapy

    Pirfenidone and similar antifibrotic agents

    Studied to slow progression of pulmonary fibrosis in HPS-1 and HPS-4.

    Clinical Trial
  • Lung Transplantation

    Lung transplant evaluation

    Considered for patients with advanced HPS-related pulmonary fibrosis.

    Available
  • Precision Genetic Counseling

    Subtype-specific genetic confirmation

    Helps tailor monitoring intensity based on the specific HPS gene involved.

    Available

Biomarkers & Monitoring

Genetic and functional testing help confirm diagnosis, subtype, and guide monitoring intensity.

When to Seek a Second Opinion

A second opinion is especially valuable for confirming subtype and planning long-term multisystem monitoring.

Clinical Trials & Research

Prognosis & Outcomes

Prognosis varies significantly by subtype: bleeding-related issues are generally manageable, but pulmonary fibrosis in HPS-1 and HPS-4 can be progressive and life-limiting.

Supportive Care

Supportive care addresses the multisystem nature of HPS, from skin protection to respiratory support.

How CancerFax Helps You Explore Treatment Options

CancerFax helps patients and families with Hermansky-Pudlak Syndrome access specialist review, coordinate multidisciplinary care across hematology and pulmonology, and explore options including antifibrotic therapy and transplant evaluation.

Get a free case review

Frequently Asked Questions

It is a rare inherited disorder causing albinism, a bleeding tendency due to platelet storage pool deficiency, and in some subtypes, progressive lung or bowel disease.

Get Expert Guidance on Hermansky-Pudlak Syndrome

Send your medical reports for a specialist review and coordinate multidisciplinary care for HPS.